We're taking a closer look at Sanofi ADS today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -9.3% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
-
Sanofi ADS has moved -14.3% over the last year compared to 17.2% for the S&P 500 -- a difference of -31.5%
-
SNY has an average analyst rating of buy and is -26.44% away from its mean target price of $61.5 per share
-
Its trailing 12 month earnings per share (EPS) is $2.99
-
Sanofi ADS has a trailing 12 month Price to Earnings (P/E) ratio of 15.1 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $4.94 and its forward P/E ratio is 9.2
-
The company has a Price to Book (P/B) ratio of 0.79 in contrast to the S&P 500's average ratio of 4.74
-
Sanofi ADS is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
-
Sanofi ADS has on average reported free cash flows of $9.25 Billion over the last four years, during which time they have grown by an an average of 3.7%